

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims:

Claim 1 (Currently Amended): An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is bactericidal against serogroups B, C, W135 and Y of *N_meningitidis*, wherein the composition comprises: (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) a 'NadA' protein in oligomeric form, a '741' protein, a '936' protein, a '953' protein and a '287' protein,

wherein:

the NadA has an amino acid sequence which: (a) has 80% [[50%]] or more identity to SEQ ID NO:2; and/or (b) comprises a fragment of at least 30 [[7]] consecutive amino acids of SEQ ID NO:1 and comprising an epitope from SEQ ID NO:1;

the 741 has an amino acid sequence which: (a) has 80% [[50%]] or more identity to SEQ ID NO:3; and/or (b) comprises a fragment of at least 30 [[7]] consecutive amino acids of SEQ ID NO:3 and comprising an epitope from SEQ ID NO:3;

the 936 has an amino acid sequence which: (a) has 80% [[50%]] or more identity to SEQ ID NO:4; and/or (b) comprises a fragment of at least 30 [[7]] consecutive amino acids of SEQ ID NO:4 and comprising an epitope from SEQ ID NO:4;

the 953 has an amino acid sequence which: (a) has 80% [[50%]] or more identity to SEQ ID NO:5; and/or (b) comprises a fragment of at least 30 [[7]] consecutive amino acids of SEQ ID NO:5 and comprising an epitope from SEQ ID NO:5; and

the 287 has an amino acid sequence which: (a) has 80% [[50%]] or more identity to SEQ ID NO:6; and/or (b) comprises a fragment of at least 30 [[7]] consecutive amino acids of SEQ ID NO:6 and comprising an epitope from SEQ ID NO:6.

Claim 2 (Original): The composition of claim 1, further comprising: (v) a conjugated serogroup A capsular saccharide antigen.

Claim 3 (Original): The composition of claim 2, wherein the serogroup A capsular saccharide is modified such that at least 20% of its monosaccharide units do not have -OH at either of the 3 and 4 positions.

Claim 4 (Canceled).

Claim 5 (Previously Presented): The composition of claim 1, wherein the conjugated saccharides are oligosaccharides.

Claim 6 (Previously Presented): The composition of claim 1, wherein the saccharides are conjugated to a carrier protein selected from: diphtheria toxoid, tetanus toxoid, *H.influenzae* protein D, and CRM₁₉₇.

Claims 7-8 (Canceled).

Claim 9 (Currently Amended): The composition of claim 1, comprising: a first polypeptide comprising amino acid sequence SEQ ID NO:2; a second polypeptide comprising amino acid sequence SEQ ID NO:7; and a third polypeptide comprising amino acid sequence SEQ ID NO:8[[:]],

Claim 10 (Previously Presented): The composition of claim 1, further comprising a saccharide antigen that protects against *H.influenzae* type B (Hib).

Claim 11 (Previously Presented): The composition of claim 1, further comprising an antigen that protects against *Streptococcus pneumoniae*.

Claim 12 (Previously Presented): The composition of claim 1 comprising an aluminium phosphate adjuvant.

Claim 13 (Previously Presented): The composition of claim 1, packaged in a hermetically-sealed container.

Claim 14 (Original): The composition of claim 13, wherein the container is a vial or a syringe.

Claims 15-16 (Canceled).

Claim 17 (Previously Presented): A method for raising an antibody response in a mammal, comprising administering a composition of claim 1 to the mammal.

Claims 18-20 (Canceled).

Claim 21 (New): The composition of claim 1, wherein:

the nadA has an amino acid sequence which: (a) has 90% or more identity to SEQ ID NO:2; and/or (b) comprises a fragment of at least 40 consecutive amino acids of SEQ ID NO: 1 and comprising an epitope from SEQ ID NO: 1;

the 741 has an amino acid sequence which: (a) has 90% or more identity to SEQ ID NO:3; and/or (b) comprises a fragment of at least 40 consecutive amino acids of SEQ ID NO:3 and comprising an epitope from SEQ ID NO:3;

the 936 has an amino acid sequence which: (a) has 90% or more identity to SEQ ID NO:4; and/or (b) comprises a fragment of at least 40 consecutive amino acids of SEQ ID NO:4 and comprising an epitope from SEQ ID NO:4;

the 953 has an amino acid sequence which: (a) has 90% or more identity to SEQ ID NO:5; and/or (b) comprises a fragment of at least 40 consecutive amino acids of SEQ ID NO:5 and comprising an epitope from SEQ ID NO:5; and

the 287 has an amino acid sequence which: (a) has 90% or more identity to SEQ ID NO:6; and/or (b) comprises a fragment of at least 40 consecutive amino acids of SEQ ID NO:6 and comprising an epitope from SEQ ID NO:6.

Claim 22 (New): The composition of claim 1, wherein:

the NadA has an amino acid sequence which: (a) has 95% or more identity to SEQ ID NO:2; and/or (b) comprises a fragment of at least 50 consecutive amino acids of SEQ ID NO: 1 and comprising an epitope from SEQ ID NO: 1;

the 741 has an amino acid sequence which: (a) has 95% or more identity to SEQ ID NO:3; and/or (b) comprises a fragment of at least 50 consecutive amino acids of SEQ ID NO:3 and comprising an epitope from SEQ ID NO:3;

the 936 has an amino acid sequence which: (a) has 95% or more identity to SEQ ID NO:4; and/or (b) comprises a fragment of at least 50 consecutive amino acids of SEQ ID NO:4 and comprising an epitope from SEQ ID NO:4;

the 953 has an amino acid sequence which: (a) has 95% or more identity to SEQ ID NO:5; and/or (b) comprises a fragment of at least 50 consecutive amino acids of SEQ ID NO:5 and comprising an epitope from SEQ ID NO:5; and

the 287 has an amino acid sequence which: (a) has 95% or more identity to SEQ ID NO:6; and/or (b) comprises a fragment of at least 50 consecutive amino acids of SEQ ID NO:6 and comprising an epitope from SEQ ID NO:6.

Claim 23 (New): An aqueous immunogenic composition which comprises: (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) a 'NadA' protein in oligomeric form, a '741' protein, a '936' protein, a '953' protein and a '287' protein, wherein:

the NadA has an amino acid sequence which: (a) has 80% or more identity to SEQ ID NO:2; and/or (b) comprises a fragment of at least 30 consecutive amino acids of SEQ ID NO: 1 and comprising an epitope from SEQ ID NO: 1;

the 741 has an amino acid sequence which: (a) has 80% or more identity to SEQ ID NO:3; and/or (b) comprises a fragment of at least 30 consecutive amino acids of SEQ ID NO:3 and comprising an epitope from SEQ ID NO:3;

the 936 has an amino acid sequence which: (a) has 80% or more identity to SEQ ID NO:4; and/or (b) comprises a fragment of at least 30 consecutive amino acids of SEQ ID NO:4 and comprising an epitope from SEQ ID NO:4;

the 953 has an amino acid sequence which: (a) has 80% or more identity to SEQ ID NO:5; and/or (b) comprises a fragment of at least 30 consecutive amino acids of SEQ ID NO:5 and comprising an epitope from SEQ ID NO:5; and

the 287 has an amino acid sequence which: (a) has 80% or more identity to SEQ ID NO:6; and/or (b) comprises a fragment of at least 30 consecutive amino acids of SEQ ID NO:6 and comprising an epitope from SEQ ID NO:6.